CXCR2 inhibition or downregulation decreased oncogenic MAPK signaling and lead to cell cycle arrest in MDS and AML CD34+/CD38-cells (Schinke et al., 2015). The gene discussed is CXCR2; the disease is acute myeloid leukemia.